v3.25.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
Service $ 40 $ 18
Operating expenses:    
Research and development 832 5,092
General and administrative 11,629 23,077
Impairment of long term assets 253
Depreciation and amortization 188 361
Total operating expenses 12,902 28,530
Loss from operations (12,862) (28,512)
Interest income (expense), net (11) 9
Gain on settlement and forgiveness of debt 2,511
Other income (expense), net: 23 (187)
Loss before income taxes (10,339) (28,690)
Income taxes (benefit)
Net loss (10,339) (28,690)
Non-controlling interest 9 (351)
Net loss attributable to BioSig Technologies, Inc. (10,330) (29,041)
Preferred stock dividend (9) (9)
Preferred stock deemed dividend (174)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (10,513) $ (29,050)
Net loss per common share, basic $ (0.75) $ (3.95)
Net loss per common share, diluted $ (0.75) $ (3.95)
Weighted average number of common shares outstanding, basic 14,041,748 7,351,794
Weighted average number of common shares outstanding, diluted 14,041,748 7,351,794

Source